CSPC Pharmaceutical Group revenue and financials
$10.00Change from previous close: +1.47%Absolute change: +$0.14
In the fiscal year ended December 2025, CSPC Pharmaceutical Group reported revenue of ¥26.01B (−10.35% year over year). Net income was ¥3.88B, a net margin of 14.9%.
Fiscal year ending in December. Sources and method on the page Methodology and sources.
At a glance
- Revenue growth
- −10.35%
- 2025 vs 2024
- Net income growth
- −10.30%
- 2025 vs 2024
- Net margin
- 14.9%
- 2024: 14.9%
Financial data
Amounts in millions of CNY; per-share values in CNY; shares in millions.
| Item | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total revenue | 26,006 | 29,009 | 31,450 | 30,937 | — |
| Cost of revenue | 8,947 | 8,711 | 9,273 | 8,680 | — |
| Gross profit | 17,059 | 20,299 | 22,177 | 22,256 | — |
| Selling, general and administrative | 7,289 | 9,742 | 10,330 | 11,510 | — |
| Research and development | 5,809 | 5,191 | 4,830 | 3,987 | — |
| Operating income | 4,181 | 5,479 | 7,016 | 6,760 | — |
| EBIT | 4,847 | 5,622 | 7,415 | 7,607 | — |
| EBITDA | 6,259 | 6,962 | 8,533 | 8,655 | — |
| Interest expense | 38.6 | 43.7 | 25.9 | 24.9 | — |
| Pre-tax income | 4,808 | 5,579 | 7,389 | 7,582 | — |
| Income tax | 932 | 1,240 | 1,317 | 1,350 | — |
| Net income | 3,882 | 4,328 | 5,873 | 6,091 | — |
| Net income to common shareholders | 3,882 | 4,328 | 5,873 | 6,091 | — |
| Basic EPS | 0.34 | 0.37 | 0.49 | 0.51 | — |
| Diluted EPS | 0.34 | 0.37 | 0.49 | 0.51 | — |
| Average shares (basic) | 11,424 | 11,738 | 11,872 | 11,917 | — |
| Average shares (diluted) | 11,424 | 11,738 | 11,873 | 11,919 | — |